Title:
KINASE INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2019/235569
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing: a novel kinase inhibitor and others; and a therapeutic agent for a disease, a drug discovery screening method and others, each utilizing the inhibitor and others. A compound represented by formula (I) or a salt thereof can inhibit multiple kinases including LATS (particularly LATS2) that is a major kinase involved in the Hippo signal transduction pathway, and can treat a disease or a damaged tissue both associated with cell proliferation failure. Accordingly, the present invention is useful in the field of study on cell functions, diseases and the like in which the Hippo signal transduction pathway is involved. The present invention is also useful in the medical field for treating the diseases and the like. {In the formula, each symbol is as defined in the description.}
More Like This:
Inventors:
NISHINO TAITO (JP)
OTSUKA KEIICHIRO (JP)
FUKAZAWA NATSUKI (JP)
NAKAJIMA HIROYUKI (JP)
AIHARA AYAKO (JP)
OTSUKA KEIICHIRO (JP)
FUKAZAWA NATSUKI (JP)
NAKAJIMA HIROYUKI (JP)
AIHARA AYAKO (JP)
Application Number:
PCT/JP2019/022536
Publication Date:
December 12, 2019
Filing Date:
June 06, 2019
Export Citation:
Assignee:
NISSAN CHEMICAL CORP (JP)
International Classes:
A61K31/165; A61K31/175; A61P1/16; A61P7/02; A61P7/04; A61P7/10; A61P9/10; A61P17/02; A61P19/00; A61P21/00; A61P25/00; A61P29/00; A61P37/00; A61P43/00; C07C251/80; C07C281/14; C07C281/18; C07C323/62; C07C337/08
Domestic Patent References:
| WO2016076359A1 | 2016-05-19 | |||
| WO2017064277A1 | 2017-04-20 | |||
| WO2019022222A1 | 2019-01-31 | |||
| WO2018198077A2 | 2018-11-01 | |||
| WO2014017513A1 | 2014-01-30 |
Foreign References:
| US5705151A | 1998-01-06 | |||
| US5994503A | 1999-11-30 | |||
| JP2018110748A | 2018-07-19 | |||
| JP2019014898A | 2019-01-31 |
Other References:
ROBERT ROSKOSKI JR., PHARMACOLOGICAL RESEARCH, vol. 100, 2016, pages 1 - 23
DORIANO F ET AL., BR J PHARMACOL, vol. 172, no. 11, 2015, pages 2675 - 2700
DRUKER BJ ET AL., NAT MED, vol. 2, no. 5, 1996, pages 561 - 566
JUSTICE RW ET AL., GENES DEV, vol. 9, no. 5, 1995, pages 534 - 546
HERGOVICH A, CELL BIOSCI, vol. 3, no. 1, 2013, pages 32
PEFANI DE ET AL., FEBS J, vol. 283, no. 8, 2016, pages 1392 - 1403
MENG Z ET AL., GENES DEV, vol. 30, no. 1, 2016, pages 1 - 17
ZHAO B ET AL., CURR OPIN CELL BIOL, vol. 20, no. 6, 2008, pages 638 - 646
IMAJO M ET AL., EMBO J, vol. 31, 2012, pages 1109 - 1122
HONG W ET AL., SEMIN CELL DEV BIOL, vol. 23, no. 7, 2012, pages 785 - 793
GUJRAL TS ET AL., PROC NATL ACAD SCI U S A, vol. 114, no. 18, 2017, pages E3729 - E3738
LEE DH ET AL., NAT COMMUN, vol. 7, 2016, pages 11961
AYLON Y ET AL., CELL DEATH DIFFER, vol. 21, no. 4, 2014, pages 624 - 633
JOHNSON R ET AL., NAT REV DRUG DISCOV, vol. 13, no. 1, 2014, pages 63 - 79
LEACH JP ET AL., NATURE, vol. 550, no. 7675, 2017, pages 260 - 264
FAN F ET AL., SCI TRANSL MED, vol. 8, no. 352, 2016, pages 352 - 108
YANG Z ET AL., MOL CELL BIOL, vol. 34, no. 9, 2014, pages 1607 - 1621
"Design of Prodrugs", 1985, ELSEVIER
SUM TH ET AL., TETRAHEDRON, vol. 71, no. 26-27, 1 July 2015 (2015-07-01), pages 4557 - 4564
SAMAL RP ET AL., CHEM BIOL DRUG DES, vol. 81, no. 6, June 2013 (2013-06-01), pages 715 - 29
See also references of EP 3804707A4
DORIANO F ET AL., BR J PHARMACOL, vol. 172, no. 11, 2015, pages 2675 - 2700
DRUKER BJ ET AL., NAT MED, vol. 2, no. 5, 1996, pages 561 - 566
JUSTICE RW ET AL., GENES DEV, vol. 9, no. 5, 1995, pages 534 - 546
HERGOVICH A, CELL BIOSCI, vol. 3, no. 1, 2013, pages 32
PEFANI DE ET AL., FEBS J, vol. 283, no. 8, 2016, pages 1392 - 1403
MENG Z ET AL., GENES DEV, vol. 30, no. 1, 2016, pages 1 - 17
ZHAO B ET AL., CURR OPIN CELL BIOL, vol. 20, no. 6, 2008, pages 638 - 646
IMAJO M ET AL., EMBO J, vol. 31, 2012, pages 1109 - 1122
HONG W ET AL., SEMIN CELL DEV BIOL, vol. 23, no. 7, 2012, pages 785 - 793
GUJRAL TS ET AL., PROC NATL ACAD SCI U S A, vol. 114, no. 18, 2017, pages E3729 - E3738
LEE DH ET AL., NAT COMMUN, vol. 7, 2016, pages 11961
AYLON Y ET AL., CELL DEATH DIFFER, vol. 21, no. 4, 2014, pages 624 - 633
JOHNSON R ET AL., NAT REV DRUG DISCOV, vol. 13, no. 1, 2014, pages 63 - 79
LEACH JP ET AL., NATURE, vol. 550, no. 7675, 2017, pages 260 - 264
FAN F ET AL., SCI TRANSL MED, vol. 8, no. 352, 2016, pages 352 - 108
YANG Z ET AL., MOL CELL BIOL, vol. 34, no. 9, 2014, pages 1607 - 1621
"Design of Prodrugs", 1985, ELSEVIER
SUM TH ET AL., TETRAHEDRON, vol. 71, no. 26-27, 1 July 2015 (2015-07-01), pages 4557 - 4564
SAMAL RP ET AL., CHEM BIOL DRUG DES, vol. 81, no. 6, June 2013 (2013-06-01), pages 715 - 29
See also references of EP 3804707A4
Attorney, Agent or Firm:
TAKASHIMA, Hajime (JP)
Download PDF: